- Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
- Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada
- Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases
- Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations
- Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
- Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation
- Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19
- Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age
- Vertex Reports Third-Quarter 2020 Financial Results
Vertex Pharmaceuticals Inc (VX1:STU) closed at 186.00, 8.14% above its 52-week low of 172.00, set on Oct 30, 2020.
172.00Oct 30 2020272.95May 18 2020
Markit short selling activity
|Market cap||59.65bn USD|
|EPS (TTM)||10.22 |
Data delayed at least 15 minutes, as of Jan 18 2021.